• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于喹唑啉的多酪氨酸激酶抑制剂:合成、建模、抗肿瘤和抗血管生成特性。

Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.

机构信息

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy.

出版信息

Eur J Med Chem. 2013 Sep;67:373-83. doi: 10.1016/j.ejmech.2013.06.057. Epub 2013 Jul 6.

DOI:10.1016/j.ejmech.2013.06.057
PMID:23900004
Abstract

In this work the synthesis and the biological evaluation of some novel anilinoquinazoline derivatives carrying modifications in the quinazoline scaffold and in the aniline moiety were reported. Preliminary cytotoxicity studies identified three derivatives, carrying dioxygenated rings fused on the quinazoline portion and the biphenylamino substituent as aniline portion, as the most effective compounds. Further investigations revealed that these compounds exhibited antiproliferative activity on a wide panel of human tumor cell lines through the inhibition of both receptor and nonreceptor TKs. Furthermore, the compound bearing the dioxolane nucleus was also able to inhibit in vivo tumor growth. Molecular modeling of these compounds into kinase domain suggested that the phenyl group allows favorable interaction energies with the target proteins: this feature is favored by fused dioxygenated ring at the 6,7 positions, whereas free rotating functions do not allow the correct placement of the molecule, thus impairing the inhibitory potency. Finally, the biphenylamino derivatives, at noncytotoxic concentrations, acted as antiangiogenic agents both in in vitro and in vivo assays.

摘要

本工作报道了一些新型的苯胺喹唑啉衍生物的合成和生物学评价,这些衍生物在喹唑啉骨架和苯胺部分进行了修饰。初步的细胞毒性研究表明,三个衍生物,即喹唑啉部分和联苯氨基取代基作为苯胺部分融合了双氧杂环戊烷环,是最有效的化合物。进一步的研究表明,这些化合物通过抑制受体和非受体 TKs,对广泛的人类肿瘤细胞系表现出抗增殖活性。此外,含有二氧戊环核的化合物也能够抑制体内肿瘤生长。将这些化合物的分子模型构建到激酶结构域中表明,苯基允许与靶蛋白产生有利的相互作用能:这一特征有利于在 6、7 位融合双氧杂环,而游离旋转功能则不允许分子的正确定位,从而降低了抑制效力。最后,在非细胞毒性浓度下,联苯氨基衍生物在体外和体内试验中均表现出抗血管生成作用。

相似文献

1
Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.基于喹唑啉的多酪氨酸激酶抑制剂:合成、建模、抗肿瘤和抗血管生成特性。
Eur J Med Chem. 2013 Sep;67:373-83. doi: 10.1016/j.ejmech.2013.06.057. Epub 2013 Jul 6.
2
Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors.新型多酪氨酸激酶抑制剂7-氨基烷氧基-4-芳氧基喹唑啉脲对肿瘤细胞生长和血管生成的抑制作用
Eur J Med Chem. 2014 May 22;79:369-81. doi: 10.1016/j.ejmech.2014.04.007. Epub 2014 Apr 5.
3
Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.发现具有双氧代环的 6-取代 4-苯胺基喹唑啉类化合物作为新型 EGFR 酪氨酸激酶抑制剂。
Bioorg Med Chem Lett. 2012 Sep 15;22(18):5870-5. doi: 10.1016/j.bmcl.2012.07.079. Epub 2012 Jul 31.
4
Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).萘酰亚胺类通过抑制拓扑异构酶 II(topo II)和受体酪氨酸激酶(RTKs)表现出体外抗增殖和抗血管生成活性。
Eur J Med Chem. 2013 Jul;65:477-86. doi: 10.1016/j.ejmech.2013.05.002. Epub 2013 May 14.
5
The anti-angiogenic and anti-tumor activity of synthetic phenylpropenone derivatives is mediated through the inhibition of receptor tyrosine kinases.合成苯丙烯酮衍生物的抗血管生成和抗肿瘤活性是通过抑制受体酪氨酸激酶来介导的。
Eur J Pharmacol. 2012 Feb 29;677(1-3):22-30. doi: 10.1016/j.ejphar.2011.12.012. Epub 2011 Dec 20.
6
Exploring epidermal growth factor receptor (EGFR) inhibitor features: the role of fused dioxygenated rings on the quinazoline scaffold.探讨表皮生长因子受体 (EGFR) 抑制剂的特性:喹唑啉骨架上融合的双氧化环的作用。
J Med Chem. 2010 Feb 25;53(4):1862-6. doi: 10.1021/jm901338g.
7
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.选择性环氧化酶-2抑制剂与表皮生长因子受体酪氨酸激酶抑制剂ZD1839及蛋白激酶A反义核酸联合使用可产生协同抗肿瘤和抗血管生成作用。
Clin Cancer Res. 2003 Apr;9(4):1566-72.
8
Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors.冠醚稠合喹唑啉类似物的合成及生物评价作为有效的 EGFR 抑制剂。
Bioorg Med Chem Lett. 2012 Oct 1;22(19):6301-5. doi: 10.1016/j.bmcl.2012.06.067. Epub 2012 Jun 28.
9
Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.新型有前景的 4-苯胺基喹唑啉类衍生物作为多靶点 RTKs 抑制剂的设计、分子对接、合成及体外和体内抗肿瘤活性。
Bioorg Med Chem. 2019 Oct 15;27(20):114938. doi: 10.1016/j.bmc.2019.06.001. Epub 2019 Jun 1.
10
Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.SIM010603 是一种口服多靶点受体酪氨酸激酶抑制剂,具有抗血管生成和抗肿瘤的临床前活性。
Cancer Chemother Pharmacol. 2012 Jan;69(1):173-83. doi: 10.1007/s00280-011-1681-1. Epub 2011 Jun 3.

引用本文的文献

1
From Ethnobotany to Biotechnology: Wound Healing and Anti-Inflammatory Properties of L. In Vitro Cultures.从民族植物学到生物技术:L 体外培养物的伤口愈合和抗炎特性。
Molecules. 2024 May 24;29(11):2472. doi: 10.3390/molecules29112472.
2
Preliminary Discovery of Small Molecule Inhibitors of Epidermal Growth Factor Receptor (EGFR) That Bind to the Extracellular Domain.与细胞外结构域结合的表皮生长因子受体(EGFR)小分子抑制剂的初步发现
Cancers (Basel). 2022 Jul 27;14(15):3647. doi: 10.3390/cancers14153647.
3
Anticancer activity of pyrimidodiazepines based on 2-chloro-4-anilinoquinazoline: synthesis, DNA binding and molecular docking.
基于2-氯-4-苯胺基喹唑啉的嘧啶二氮杂卓类化合物的抗癌活性:合成、DNA结合及分子对接
RSC Adv. 2021 Jul 1;11(38):23310-23329. doi: 10.1039/d1ra03509f.
4
Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro).基于细胞的高通量筛选技术用于发现针对 SARS-CoV-2 主蛋白酶(3CLpro)的抗病毒抑制剂
Mol Biotechnol. 2021 Mar;63(3):240-248. doi: 10.1007/s12033-021-00299-7. Epub 2021 Jan 19.
5
Comparative Assessment of Protein Kinase Inhibitors in Public Databases and in PKIDB.比较公共数据库和 PKIDB 中的蛋白激酶抑制剂。
Molecules. 2020 Jul 15;25(14):3226. doi: 10.3390/molecules25143226.
6
Kinase Inhibitory Activities and Molecular Docking of a Novel Series of Anticancer Pyrazole Derivatives.新型抗癌吡唑衍生物的激酶抑制活性及分子对接研究。
Molecules. 2018 Nov 24;23(12):3074. doi: 10.3390/molecules23123074.
7
Design, Synthesis and Docking Studies of Novel Macrocyclic Pentapeptides as Anticancer Multi-Targeted Kinase Inhibitors.新型大环五肽作为抗癌多靶点激酶抑制剂的设计、合成及对接研究。
Molecules. 2018 Sep 20;23(10):2416. doi: 10.3390/molecules23102416.
8
An insight into the therapeutic potential of quinazoline derivatives as anticancer agents.喹唑啉衍生物作为抗癌剂的治疗潜力洞察。
Medchemcomm. 2017 Apr 7;8(5):871-885. doi: 10.1039/c7md00097a. eCollection 2017 May 1.
9
Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido[2,3-d]pyrimidine scaffold.基于吡啶并[2,3-d]嘧啶骨架的多靶点激酶抑制剂的抗癌评估与分子建模
J Enzyme Inhib Med Chem. 2018 Dec;33(1):546-557. doi: 10.1080/14756366.2018.1437729.
10
Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N'-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily.用苯胺嘧啶靶向激酶:N-苯基-N'-[4-(嘧啶-4-基氨基)苯基]脲衍生物作为III类受体酪氨酸激酶亚家族选择性抑制剂的发现。
Sci Rep. 2015 Nov 16;5:16750. doi: 10.1038/srep16750.